4.1.4.2.1.1. comparison different anticholinergic agents. head-to-head comparison trials efficacy adverse effects different anticholinergic agents interest decision-making. network meta-analysis sr revealed superior anticholinergic preparation cure improvement . clinically significant differences anticholinergics voiding ui outcomes. single anticholinergic agent improved qol another . conflicting results reported another network meta-analysis 53 rcts compared efficacy tolerability solifenacin 5 mg/day oral anticholinergics treatment adults oab symptoms . solifenacin 5 mg/day significantly effective tolterodine 4 mg/day reducing uui episodes, significantly less effective solifenacin 10 mg/day reducing micturition episodes. solifenacin 5 mg/day showed significantly lower risk dry mouth compared anticholinergics significant differences risk blurred vision constipation. network meta-analysis 128 rcts including genders showed anticholinergics worse placebo terms dry mouth transdermal oxybutynin smallest difference . dry mouth prevalent reported adverse effect. extended-release formulations associated lower rates dry mouth ir preparations . oxybutynin ir shows higher rates dry mouth tolterodine ir trospium ir lower rates dry mouth darifenacin, 15 mg daily . overall, oxybutynin er causes higher rates dry mouth tolterodine er does, although incidence moderate severe dry mouth similar. transdermal oxybutynin lower rate dry mouth oxybutynin ir tolterodine er overall higher rate withdrawal due adverse skin reactions . solifenacin 10 mg daily higher rates dry mouth tolterodine er . fesoterodine 8 mg daily higher rate dry mouth tolterodine 4 mg daily [168-170]. similar discontinuation rates observed, irrespective differences occurrence dry mouth. notable nearly primary studies category industry sponsored. general, studies designed achieve regulatory approval. upward dose titration often included protocol experimental arm comparator arm. short treatment durations (twelve weeks) primary outcome change oab symptoms rather cure of, improvement in, uui, generally analysed secondary outcomes. clinical utility trials real-life practice therefore debatable. trials low moderate quality .